Reading http://www.bloomberg.com/news/2014-...raise-up-to-2-4-billion-in-australia-ipo.html Healthscope looks like having an Enterprise Value (market cap plus debt) post-IPO of around $4 billion. This financial year it is expecting a loss of around $145 million on $2.3 billion in revenues. Konekt is a minnow in comparison, with revenue around $32 million and no earnings forecast for this FY. But our enterprise value (market cap minus cash) is only $7 million or so...
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
